Indivior Pharmaceuticals (INDV) Equity Average (2022 - 2026)

Indivior Pharmaceuticals' Equity Average history runs 5 years deep, the most recent figure standing at -$121.0 million for Q1 2026.

• In Q1 2026, Equity Average rose 61.09% year-over-year to -$121.0 million; the TTM figure through Mar 2026 stood at -$121.0 million (up 61.09% YoY), while the FY2025 annual figure was -$217.5 million, up 16.51% from the prior year.
• Equity Average was -$121.0 million for Q1 2026 at Indivior Pharmaceuticals, up from -$152.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $53.0 million in Q4 2022 to a low of -$323.5 million in Q4 2024.
• Historically, Equity Average has averaged -$195.1 million across 5 years, with a median of -$221.0 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Equity Average plunged 287.74% in 2023, then jumped 61.09% in 2026.
• A 5-year view of Equity Average shows it stood at $53.0 million in 2022, then slumped by 287.74% to -$99.5 million in 2023, then slumped by 225.13% to -$323.5 million in 2024, then surged by 52.86% to -$152.5 million in 2025, then advanced by 20.66% to -$121.0 million in 2026.
• The last three Equity Average figures came in at -$121.0 million (Q1 2026), -$152.5 million (Q4 2025), and -$232.0 million (Q3 2025), per Business Quant data.